Trademark Search in Canada

DICERNA PHARMACEUTICALS & DESIGN

View On IC.GC.CA

REGISTERED

on 15 Jun 2022

Last Applicant/ Owned by

DICERNA PHARMACEUTICALS INC.

87 Cambridgepark DriveCambridge, MA 02140

Serial Number

1929863 filed on 9^th Nov 2018

Registration Number

TMA1131818 registered on 15^th Jun 2022

Registration expiry Date

15^th Jun 2032

Correspondent Address

CPST INTELLECTUAL PROPERTY INC.

130 Queens Quay EastEast Tower, Suite 809Toronto,

ONTARIO

M5A0P6

DICERNA PHARMACEUTICALS & DESIGN

Trademark usage description

pharmaceutical preparations for the treatment of various diseases, namely, rare metabolic, endocrine, cardiac, oncological, gastrointestinal, nephrolo Read More

Vienna Information

1 . 13 . 1

Armillary spheres, planetaria, astronomic orbits, atomic models, molecular modelsSphères armillaires, planétariums, orbites astronomiques, schémas d'atomes, schémas de molécules

1 . 13 . 15

Atomic models, molecular models, representations of human, animal or vegetal cellsSchémas atomiques, schémas de molécules, représentations de cellules humaines, animales ou végétales

26 . 3 . 1

One triangleUn triangle

26 . 3 . 24

Triangles with dark surfaces or parts of surfacesTriangles avec surface ou partie de la surface foncée

Classification Information

Class [005]
Pharmaceutical preparations for the treatment of various diseases, namely, rare metabolic, endocrine, cardiac, oncological, gastrointestinal, nephrological, autoimmune, and neurological diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare metabolic, endocrine, cardiac, oncological, gastrointestinal, nephrological, autoimmune, and neurological diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies.

Classification kind code

Class [042]
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development for the treatment of various diseases, namely rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and cancers and viral infections; scientific investigations in the fields of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and cancers and viral infections for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.

Classification kind code

Mark Details

Serial Number

1929863

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 190 on 2^th Mar 2022	Registration Pending
Submitted for opposition 42 on 8^th Dec 2021	Advertised
Submitted for opposition 27 on 15^th Nov 2021	Approval Notice Sent
Submitted for opposition 26 on 15^th Nov 2021	Approved
Submitted for opposition 48 on 20^th Oct 2021	Agent Changed
Submitted for opposition 22 on 14^th May 2021	Search Recorded
Submitted for opposition 20 on 14^th May 2021	Examiner's First Report
Submitted for opposition 31 on 15^th Nov 2018	Formalized
Submitted for opposition 1 on 13^th Nov 2018	Created
Submitted for opposition 30 on 9^th Nov 2018	Filed